TICKERNERD
Menu
SRRKSRRKHealthcare · Biotechnology

SRRK Stock Forecast: Scholar Rock Holding Corp. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$47
+1.41% on the day

The 18 Wall Street analysts covering Scholar Rock Holding Corp. hold a median 12-month price target of $72 — +52.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 3 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.7B
Ticker Nerd rank
35 / 100
Median analyst target
$72
Analysts covering
18
Revenue$0.0
Operating income−$108.9M
Net income−$109.9M
Free cash flow−$70.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.7%
1M
−16.6%
YTD
+6.3%
1Y
+33.0%
From 52W high
−22.0%
From 52W low
+67.7%
$28
$60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SRRK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Scholar Rock Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
77
Accruals
74
Value
71
Revisions
54
Volatility
48
Growth
35
Size
21
Quality
21
Issuance
7

Momentum (77): The shares have been drifting up relative to others.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SRRK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SRRK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70$80$90Jan 26Apr 26Jul 26Oct 26SRRKHigh $84Median $72Low $58

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
17 Buy1 Hold0 Sell
Low $58Median $72High $84

The green dot is the last close — the median target sits +52.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
24 Sept 2026Truist SecuritiesMaintainsBuy$76 → $77
21 Sept 2026JP MorganMaintainsOverweight$63 → $70
15 Sept 2026BarclaysDowngradeEqual-Weight—
15 Sept 2026BarclaysDowngradeEqual-Weight$55 → $58
15 Sept 2026Evercore ISI GroupMaintainsOutperform$65 → $72
15 Sept 2026Evercore ISI GroupMaintainsOutperform—
15 Sept 2026HC Wainwright & Co.MaintainsBuy—
15 Sept 2026HC Wainwright & Co.MaintainsBuy$65 → $70
15 Sept 2026JefferiesMaintainsBuy—
15 Sept 2026JefferiesMaintainsBuy$57 → $65
15 Sept 2026Piper SandlerMaintainsOverweight$60 → $75
15 Sept 2026Piper SandlerMaintainsOverweight—
15 Sept 2026WedbushMaintainsOutperform—
15 Sept 2026WedbushMaintainsOutperform$64 → $70
14 Sept 2026BMO CapitalMaintainsOutperform—
14 Sept 2026BMO CapitalMaintainsOutperform$76 → $84
14 Sept 2026CitigroupMaintainsBuy—
14 Sept 2026CitigroupMaintainsBuy$60 → $74
14 Sept 2026Raymond JamesMaintainsStrong Buy$65 → $72
14 Sept 2026Raymond JamesMaintainsStrong Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRRK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SRRK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Scholar Rock Holding Corp. returned +33.0% against +16.2% for the S&P 500, dividends included.

SRRK vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26SRRKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SRRK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
6
Fundamentals

Scholar Rock Holding Corp. (SRRK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−14.2×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
22.4×

Cheaper than 4% of US stocks

EV / EBITDA
−13.4×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−167.8%

Higher than 9% of US stocks

Return on assets
−58.8%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Scholar Rock Holding Corp. (SRRK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Scholar Rock Holding Corp. has a market value of $5.7B and an enterprise value of $5.4B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$408.6M.

  • Diluted earnings per share, trailing twelve months: $−3.45.

  • Free cash flow in the twelve months to 30 June 2026: −$297.0M.

  • Shares outstanding: 121.6M.

  • Trailing P/E: −14.2×; forward P/E: −18.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Scholar Rock Holding Corp. employs 289 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

SRRK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SRRKScholar Rock Holding Corp.$5.7B
35
KODKodiak Sciences, Inc.$5.7B
49
ORKAOruka Therapeutics, Inc.$5.6B
40
CGONCG Oncology, Inc.$5.9B
17
LGNDLigand Pharmaceuticals, Inc.$6.0B
70
MIRMMirum Pharmaceuticals, Inc.$5.4B
66
TVTXTravere Therapeutics, Inc.$5.4B
86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Scholar Rock Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SRRK news & analysis

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 21 Sept 2026neutral

Scholar Rock announced it granted inducement equity awards covering an aggregate of 83,102 shares of common stock to ten newly hired employees, comprising stock options for 23,801 shares and restricted stock units covering 59,301 shares, under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The grants indicate recent workforce additions and potentially some share dilution, which Scholar Rock watchers may track as they follow the company's hiring and equity plans.

Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

Seeking Alpha · 15 Sept 2026positive

Following FDA approval of ISEMBYLD (apitegromab) for spinal muscular atrophy in patients aged two years and older, Seeking Alpha reiterates a "Strong Buy" rating on Scholar Rock. The article notes expansion potential into younger populations, subcutaneous formulations, and new indications like FSHD, plus planned regulatory filings in Europe and Japan.

Why it matters — The FDA approval and pipeline expansion into new indications and populations represent key growth catalysts that Scholar Rock watchers would track for the company's commercial trajectory.

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Benzinga · 15 Sept 2026neutral

The article lists top Wall Street analyst downgrades for Tuesday, including a Cellectis analyst who is no longer bullish. The item notes that analysts changed their outlook on several prominent names, with a full view of rating changes available on the analyst ratings page.

Why it matters — Scholar Rock Holding Corp. (SRRK) watchers would care because this roundup highlights market-wide analyst rating changes that could provide context for sentiment in the biotech sector.

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

Seeking Alpha · 14 Sept 2026positive

Scholar Rock Holding Corporation holds a discussion detailed in a Seeking Alpha transcript regarding the FDA approval and clinical impact of ISEMBYLD in the treatment of spinal muscular atrophy (SMA). The transcript focuses on the company's drug ISEMBYLD and its regulatory and clinical significance in SMA treatment.

Why it matters — A transcript centered on the FDA approval and clinical impact of ISEMBYLD would matter to Scholar Rock watchers as it highlights the progress and potential of the company's lead SMA therapy.

Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

Benzinga · 14 Sept 2026positive

The U.S. Food and Drug Administration approved Scholar Rock's ISEMBYLD (apitegromab-mstn), a muscle-targeted treatment for spinal muscular atrophy, for adults and pediatric patients aged 2 years and older. The approval marks the company's first muscle-targeted treatment for SMA.

Why it matters — SRRK watchers would care because this FDA approval represents a significant commercial milestone and the company's first approved muscle-targeted therapy for SMA, which the firm describes as a defining moment.

FAQ

Frequently asked questions about SRRK stock

What is the SRRK stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Scholar Rock Holding Corp. have a median 12-month price target of $72, with estimates ranging from $58 to $84. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SRRK stock a buy right now?

Of the 18 analysts covering Scholar Rock Holding Corp., 17 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scholar Rock Holding Corp. 35 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SRRK?

As at 3 Oct 2026, Scholar Rock Holding Corp. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (77 of 100).

Will SRRK stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +52.7% from the last close, and Ticker Nerd's factor model ranks Scholar Rock Holding Corp. 35 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SRRK stock forecast for 2030?

No analyst covering Scholar Rock Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRRK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $58 to $84 over the next 12 months.

How has SRRK stock performed over the past year?

Scholar Rock Holding Corp. returned +33.0% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Scholar Rock Holding Corp. do?

Scholar Rock Holding Corporation Common Stock represents an equity interest in Scholar Rock Holding Corporation, a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with an emphasis on rare neuromuscular disorders such as spinal muscular atrophy (SMA). The company’s current pipeline is centered on apitegromab, its lead investigational therapy, alongside additional programs in neuromuscular and other severe disease areas where protein growth factor signaling plays a key role.

What is the latest news on SRRK?

The most recent item we track (Business Wire, 21 Sept 2026): "Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Scholar Rock announced it granted inducement equity awards covering an aggregate of 83,102 shares of common stock to ten newly hired employees, comprising stock options for 23,801 shares and restricted stock units covering 59,301 shares, under Nasdaq Listing Rule 5635(c)(4).

Company

About Scholar Rock Holding Corp.

Scholar Rock Holding Corporation Common Stock represents an equity interest in Scholar Rock Holding Corporation, a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with an emphasis on rare neuromuscular disorders such as spinal muscular atrophy (SMA). The company’s current pipeline is centered on apitegromab, its lead investigational therapy, alongside additional programs in neuromuscular and other severe disease areas where protein growth factor signaling plays a key role. Scholar Rock applies its myostatin biology platform to advance treatments intended to address significant unmet medical needs in patients across pediatric and adult populations. The company is headquartered in Cambridge, Massachusetts, and its common stock is used by investors to track the market’s view of its clinical development progress, regulatory milestones, and broader biopharmaceutical execution.

CEO Mr. David L. Hallal · 289 employees · United States · https://www.scholarrock.com